Orion Pharma Expands Europe Biosimilar Portfolio with Shilpa
ESPOO, Finland, June 30, 2026 Orion Pharma has announced a strategic agreement with Shilpa Biologicals Private Limited, a wholly...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
ESPOO, Finland, June 30, 2026 Orion Pharma has announced a strategic agreement with Shilpa Biologicals Private Limited, a wholly...
ST. LOUIS, Mo., June 30, 2026 Aurenar has announced that the U.S. Food and Drug Administration (FDA) has granted...
